Meeting
2017 Genitourinary Cancers Symposium
Boosting long-term immune responses to sipuleucel-T (sip-T) by retreatment of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Authors
Tomasz M. Beer
Knight Cancer Institute, Oregon Health & Science University, Portland, OR
Tomasz M. Beer , John Corman , Raymond S. Lance , Dwayne Campogan , Tuyen Vu , Heather Haynes , Nancy N. Chang , Nadeem Anwar Sheikh , Brendan D. Curti
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT01338012
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 196)
DOI
10.1200/JCO.2017.35.6_suppl.196
Abstract #
196
Poster Bd #
G25
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
The association of humoral antigen spread (AgS) with cytotoxic T lymphocyte (CTL) activity after sipuleucel-T (sip-T) treatment in two phase II clinical studies: STAMP and STRIDE.
First Author: Daniel Peter Petrylak
Poster
2017 Genitourinary Cancers Symposium
Antigen spread (AgS) after sipuleucel-T (sip-T): A cross-trial comparison of 4 sip-T clinical trials of patients (pts) with prostate cancer (PC).
First Author: Lawrence Fong
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Cytokine profile of sipuleucel-T (sip-T) in differentiating reactivation of latent immunity from de novo immune responses.
First Author: Charles G. Drake
Poster
2017 Genitourinary Cancers Symposium
Long-term follow-up from STAMP, a phase II trial, evaluating sipuleucel-T and concurrent (CON) vs sequential (SEQ) abiraterone acetate + prednisone in metastatic castration-resistant prostate cancer patients (pts).
First Author: Eric Jay Small